PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer - LARVOL DELTA

Effectiveness of 13-valent Pneumococcal Conjugate Vaccine against Vaccine-type Invasive Pneumococcal Disease in Children under 5 Years Old in Zhejiang, China: a case-control study. (PubMed, Int J Infect Dis) - "PCV13 is highly effective at preventing VT- IPD in children in China. Findings underscore PCV13's public health value and provide local evidence that could support decision-making for routine childhood immunization programme."

Journal • Infectious Disease • Influenza • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan (clinicaltrialsregister.eu) - P3 | N=540 | Sponsor: Pfizer Inc.

New P3 trial • Dermatology • Infectious Disease • Pneumococcal Infections • Pneumonia

PCV20 FOR HIGH-RISK POPULATIONS: A COST-UTILITY ANALYSIS FROM THE BRAZILIAN PUBLIC HEALTH SYSTEM PERSPECTIVE (ISPOR 2026) - "These results support the use of PCV20 as a simplified and cost-effective strategy for preventing PD in vulnerable people, supporting its inclusion into the NIP."

Clinical • HEOR • CNS Disorders • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

IM-101_MG_2.1: A Phase 1b/2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of IM-101 in Adult Participants with Generalized Myasthenia Gravis and Ocular Myasthenia Gravis (clinicaltrialsregister.eu) - P1/2 | N=83 | Not yet recruiting | Sponsor: Immunabs Inc.

New P1/2 trial • CNS Disorders • Myasthenia Gravis

A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks) (clinicaltrials.gov) - P3 | N=600 | Recruiting | Sponsor: CanSino Biologics Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

A Multi-Country Comparison of Number Needed to Vaccinate for PCV20 and PCV15 in Infants. (PubMed, Vaccines (Basel)) - "To achieve the same disease reduction as PCV20, over five times as many children would need to be vaccinated with PCV15. These findings suggest PCV20 may offer greater public health impact compared with PCV15 in infant immunization programs."

Journal • Infectious Disease • Pediatrics • Pneumococcal Infections

A comparative analysis of pediatric pneumococcal vaccination strategies: a dynamic model of PCV20 vs. PCV15 and PCV13. (PubMed, Vaccine) - "Pediatric PCV20 use is projected to reduce pneumococcal disease burden and healthcare costs in the US compared with PCV15 or PCV13. Results support the health and economic value of adopting a higher-valent pediatric vaccination approach using PCV20."

Journal • Infectious Disease • Otorhinolaryngology • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults (clinicaltrials.gov) - P1 | N=400 | Completed | Sponsor: Pfizer | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Pneumococcal Infections

A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant (clinicaltrials.gov) - P1 | N=200 | Active, not recruiting | Sponsor: Pfizer | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Pneumococcal Infections

The effect of pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine on nasopharyngeal colonisation following human infection challenge with serotype 3 and serotype 6B (PREVENTING PNEUMO 2): a double-masked, randomised, controlled, phase 4 trial. (PubMed, Lancet Microbe) - P4 | "Our findings indicate partial direct protection by PCV13 against Spn3 colonisation acquisition, with differential protection against the clades and no protection by PPV23 against clade Iα. By contrast, PCV13 protected against Spn6B colonisation for at least 6 months. These findings align with epidemiological evidence, indicating that, although PCV13 vaccination against Spn6B offers sustained direct and indirect protection, its effect on Spn3 colonisation and therefore indirect protection is limited. Direct vaccination of at-risk adults might therefore be more appropriate than relying solely on herd immunity from paediatric programmes. The development of next-generation pneumococcal vaccines and further immunological analysis are needed to optimise protection against Spn3."

Journal • P4 data • Infectious Disease • Pediatrics • Pneumococcal Infections • Pneumonia

An overview of the clinical development of the 20-valent pneumococcal conjugate vaccine in adults. (PubMed, Hum Vaccin Immunother) - "Immunobridging of PCV20 responses to adults 60-64 y of age supports PCV20 use in adults 18 through 59 y of age, including those at increased risk of pneumococcal disease. Additionally, PCV20 elicited functional responses to all 20 vaccine serotypes in adults ≥65 y old who were previously vaccinated with PCV13 and/or PPSV23."

Journal • Review • Infectious Disease • Pneumococcal Infections • Pneumonia

Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (clinicaltrials.gov) - P1/2 | N=750 | Active, not recruiting | Sponsor: Sanofi Pasteur, a Sanofi Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Meningococcal Infections • Pediatrics

MEQ00064: Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (clinicaltrials.gov) - P3 | N=1528 | Completed | Sponsor: Sanofi Pasteur, a Sanofi Company | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Meningococcal Infections • Pediatrics

PRO-PCV-1002: A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (clinicaltrials.gov) - P1 | N=140 | Completed | Sponsor: Sinovac Research and Development Co., Ltd. | Active, not recruiting ➔ Completed | Trial completion date: Jul 2025 ➔ Mar 2025

Trial completion • Trial completion date • Infectious Disease • Pneumococcal Infections

Clinical Trial of PCV24 in Infants Aged 2-23 Months (clinicaltrials.gov) - P1 | N=180 | Recruiting | Sponsor: Sinovac Life Sciences Co., Ltd. | Not yet recruiting ➔ Recruiting | Trial primary completion date: Sep 2025 ➔ Jun 2026

Enrollment open • Trial primary completion date • Infectious Disease • Pneumococcal Infections

PRO-PCV-3001: Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine (clinicaltrials.gov) - P3 | N=3080 | Recruiting | Sponsor: Sinovac Life Sciences Co., Ltd. | Trial completion date: Apr 2026 ➔ Jul 2026 | Trial primary completion date: Oct 2025 ➔ May 2026

Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

Clinical Trial of PCV24 in Children Aged 2-17 Years (clinicaltrials.gov) - P1 | N=119 | Completed | Sponsor: Sinovac Life Sciences Co., Ltd. | Recruiting ➔ Completed

Trial completion • Infectious Disease • Pneumococcal Infections

Cost-effectiveness analysis of a 20-valent pneumococcal conjugate vaccine for pneumococcal disease prevention in the Slovak pediatric population. (PubMed, J Med Econ) - "Direct and indirect vaccine effects (VE) were estimated from vaccine impact, effectiveness, and clinical studies of PCV7 and PCV13...Implementing PCV20 into the Slovakian pediatric NIP is projected to yield the most significant clinical and economic benefits compared to the two lower-valent PCVs, due to its more extensive protection against a broader range of pneumococcal serotypes. Despite an additional cost of dose and visit, PCV20 was estimated to be cost-effective at the Slovak WTP threshold versus other SoC options over a 10-year time horizon."

HEOR • Journal • Infectious Disease • Otorhinolaryngology • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Clinical effectiveness and impact of 13-valent pneumococcal conjugate vaccines in preventing invasive pneumococcal disease among children with risk conditions: A systematic literature review. (PubMed, Hum Vaccin Immunother) - "Of 3008 records identified, full texts of 189 studies (6.3%) were reviewed and 11 (0.4%) studies evaluating PCV13 alone or in combination with PCV7 were included...PCV impact, as measured by incidence rate reductions, among children with HIV varied by comparison period, age group and outcome and ranged from 9.1% to 81% for any IPD. These findings support PCV vaccination for children with risk conditions although evidence was limited and heterogeneous."

Journal • Review • Cardiovascular • Genetic Disorders • Heart Failure • Hematological Disorders • Human Immunodeficiency Virus • Infectious Disease • Oncology • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases • Sickle Cell Disease • Transplantation

PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months (clinicaltrials.gov) - P2 | N=480 | Recruiting | Sponsor: Shanghai Reinovax Biologics Co.,LTD

New P2 trial • Infectious Disease • Pneumococcal Infections

Determining the dose-response relationship for pneumococcal conjugate vaccines: a nested analysis of the fractional dose PCV trial. (PubMed, Vaccine) - P4 | "Our findings suggest that available PCV10/13 could be reformulated to optimize protective responses."

Clinical • Journal • Infectious Disease • Pneumococcal Infections

Immunogenicity and safety of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults ≥18 years of age in India: A phase 3 single-arm trial. (PubMed, Hum Vaccin Immunother) - P3 | "Consistent with previous trials, PCV20 elicited robust immune responses to all 20 serotypes following a single dose and was well tolerated with an acceptable safety profile in Indian adults ≥18 y of age. NCT05875727."

Journal • P3 data • CNS Disorders • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - P2 | N=42 | Active, not recruiting | Sponsor: Jennifer Woyach | Trial completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma • TP53

Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years (clinicaltrials.gov) - P1 | N=230 | Active, not recruiting | Sponsor: Shanghai Reinovax Biologics Co.,LTD | Enrolling by invitation ➔ Active, not recruiting | Trial primary completion date: Feb 2026 ➔ May 2025

Enrollment closed • Trial primary completion date • Infectious Disease • Pneumococcal Infections

A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants (clinicaltrials.gov) - P2 | N=537 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P2 trial • Infectious Disease